203 related articles for article (PubMed ID: 26967818)
1. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.
Binder M; Rajkumar SV; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
Blood Cancer J; 2016 Mar; 6(3):e401. PubMed ID: 26967818
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience.
Jung HA; Jang MA; Kim K; Kim SH
Ann Lab Med; 2018 May; 38(3):196-203. PubMed ID: 29401553
[TBL] [Abstract][Full Text] [Related]
3. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
Laï JL; Zandecki M; Mary JY; Bernardi F; Izydorczyk V; Flactif M; Morel P; Jouet JP; Bauters F; Facon T
Blood; 1995 May; 85(9):2490-7. PubMed ID: 7537117
[TBL] [Abstract][Full Text] [Related]
4. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities.
Lim JH; Seo EJ; Park CJ; Jang S; Chi HS; Suh C; Kim H; Kim SR
Eur J Haematol; 2014 Apr; 92(4):313-20. PubMed ID: 24372944
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
8. Prediction of cytogenetic abnormalities with gene expression profiles.
Zhou Y; Zhang Q; Stephens O; Heuck CJ; Tian E; Sawyer JR; Cartron-Mizeracki MA; Qu P; Keller J; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2012 May; 119(21):e148-50. PubMed ID: 22496154
[TBL] [Abstract][Full Text] [Related]
9. [The significance and current diagnostic options of cytogenetic changes in multiple myeloma].
Kuglík P; Filková H; Oltová A; Hájek R
Vnitr Lek; 2006 Nov; 52 Suppl 2():76-8. PubMed ID: 18175433
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities.
Kim SY; Koo M; Park Y; Kim H; Choi Q; Song IC; Jo DY; Kim J; Kwon GC; Koo SH
Blood Cells Mol Dis; 2019 Jul; 77():120-128. PubMed ID: 31059941
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.
Binder M; Rajkumar SV; Ketterling RP; Greipp PT; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
Blood Cancer J; 2017 Sep; 7(9):e600. PubMed ID: 28862698
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
14. [High risk cytogenetic abnormalities in patients with multiple myeloma].
Legües ME; Morales P; Valenzuela M; Encina A; Martí MJ; Bascuñán C; Cornejo P; Peña C; Undurraga MS
Rev Med Chil; 2019; 147(1):61-64. PubMed ID: 30848766
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
Hao S; Lin P; Medeiros LJ; Fang L; Carballo-Zarate AA; Konoplev SN; Sargent RL; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Lu X
Mod Pathol; 2017 Oct; 30(10):1378-1386. PubMed ID: 28664940
[TBL] [Abstract][Full Text] [Related]
16. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal fluorescence
Merz M; Jauch A; Hielscher T; Mai EK; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf I; Scheid C; Haenel M; Weisel K; Goldschmidt H; Hillengass J
Haematologica; 2017 Aug; 102(8):1432-1438. PubMed ID: 28495913
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Specchia G; Lefrere F; Sica S; Mancini M; Venditti A; Hagemeijer A; Becker H; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S
Ann Hematol; 2018 Oct; 97(10):1785-1795. PubMed ID: 29926156
[TBL] [Abstract][Full Text] [Related]
20. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Jacobson J; Barlogie B; Shaughnessy J; Drach J; Tricot G; Fassas A; Zangari M; Giroux D; Crowley J; Hough A; Sawyer J
Br J Haematol; 2003 Aug; 122(3):430-40. PubMed ID: 12877670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
